



Market Recognition

Viva Biotech Included as Constituent Stock of MSCI China Small Cap Index

On May 12, 2021, Viva Biotech announced that the company has been included as a constituent stock of the MSCI China Small Index, according to the latest semi-annual review results of the world's leading index company MSCI.



This inclusion of the MSCI China Small Cap Index fully reflects the capital market's recognition towards the development prospects of Viva Biotech's dual-engine driving business model and one-stop integrated drug R&D and production platform. It is expected to further expand Viva Biotech's influence and popularity in the international capital market and to attract more diversified investors.

Viva Biotech Won the Frost & Sullivan "2021 Greater China CRO Entrepreneurial Company of the Year"



On April 15, 2021, Frost & Sullivan, an international authoritative consulting agency, announced the selection results of the 2021 Best Practices Awards. As a comprehensive one-stop drug R&D and production service platform, Viva Biotech won the "2021 Greater China CRO Entrepreneurial Company of the Year".



Company News

Langhua Pharmaceutical's CMC Business Came to the Fore, Promoting the R&D of VivaVision's Innovative Drugs

In June 2021, Zhejiang Langhua Pharmaceutical has successfully provided support and services for the scale-up production of clinical samples of VivaVision's VVN001. The successful implementation of VVN001 clinical sample supportive service confirms the vertical client diversion effect of Viva Biotech from the front-end of new drug R&D, and further highlights the strategic synergy between Viva Biotech and Langhua Pharmaceutical in the fields of R&D and the production of innovative drugs.



Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate Early Drug Discovery through AI Technology

On May 10-11, 2021, the first generation of China Biocomputing Conference was successfully launched in Suzhou. Viva Biotech was invited to attend the conference and announced a strategic collaboration agreement with BioMap, a bio-computing driven innovative drug R&D company of Baidu. This collaboration will be based on the AI + biological computing engine from BioMap, with the structure-based drug discovery platform from Viva Biotech, to jointly accelerate the R&D of novel drugs.



Material Deal

Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci



On June 15, 2021, Totient, a biotech company that harness human immune responses to identify novel antibodies and their therapeutic targets, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. AbSci's acquisition of Totient also further demonstrates the successful operability of Viva's EFS model and provides an excellent example for an investment exit under this cooperative model.

Investment Progress

AlxplorerBio Completed an Angel Round of Financing of RMB50 Million



On April 26, 2021, AlxplorerBio, an AI new drug research and development company, announced the completion of an angel round of financing of RMB50 million. This round of financing was led by BioMap, and co-invested by Viva. BioMap and Viva Biotech will provide AlxplorerBio with comprehensive and in-depth support in AI technology, computing power, underlying multi-dimensional data, protein structure analysis, and pharmaceutical testing, etc..

VivaVision Completed Series D Financing of RMB300 Million, Lead by Sequoia



On April 19, 2021, VivaVision, a leading ophthalmology novel drug developer, announced that it has completed a RMB300 million Series D financing lead by Sequoia. This round of funding will be used to support the clinical development of several innovative ophthalmic drug products, including Phase II US clinical study of the ongoing dry eye disease project VVN001.

TechnoDerma Medicines Completed Tens of Millions in Series A Financing, Lead by CDH VGC



On April 7, 2021, TechnoDerma Medicines, which focused on the development of First-in-Class new drugs for skin-related diseases, announced the completion of tens of millions Series A financing lead by CDH VGC. The fund will be used to advance the Company's pipeline clinical trials and follow-up research and development, further expand the indications, and strengthen the development of the research and the team.

Business Progress



Shanghai EPN and BioMap Reached a Strategic Cooperation

On April 14, 2021, Shanghai EPN has reached a strategic cooperation agreement with BioMap to focus on autoimmune diseases cooperative development of multi-omics joint analysis of specific clinical problems and functional omics disease maps of specific diseases.

Research & Development Progress



QureBio Announced the Enrollment of First Patient in Phase I Clinical Trial of Claudin18.2/PD-L1 Bispecific Antibody

In June 2021, QureBio, a biotech company that dedicated to the development of innovative macromolecular biological drugs with independent intellectual property rights, announced that its phase I clinical trial of Q-1802 (Claudin18.2 / PD-L1) bispecific antibody for the treatment of advanced solid tumors has successfully completed its first patient enrollment.

Anji Pharma to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials; Anji Pharma Launched Phase 3 Trial for ANJ900 and Accelerated Phase II Clinical Study of ANJ908

In June 2021, Anji Pharma announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute ([Learn More](#)). In the same month, Anji Pharma initiated a pivotal trial of ANJ900 (delayed-release metformin) in patients with Type 2 diabetes (T2D), including those with varying stages of renal disease ([Learn More](#)). In April 2021, the world's first mechanism of functional constipation treatment drug pradiagstat (ANJ908) initiated its Phase II clinical proof of concept research simultaneously in the United States and China.



TechnoDerma Medicines Announced New Progress in Phase I Clinical Trials of TDM-105795 in the U.S.

In May 2021, Jiaying TechnoDerma Medicines announced that its phase I clinical trial of the world's leading small molecule drug TDM-105795 successfully completed the first human administration (FIH) in healthy male subjects with androgenetic alopecia (AGA) in the skin clinical research center-TCR (Therapeutics Clinical Research), San Diego, U.S..



About Viva Biotech

Listing Date

2019.05.09

Price (2021.6.24)

HKD 11.02

52 WK Range

HKD 6.05 - 11.64

Market Cap (2021.6.24)

HKD 21.23B

Viva Biotech's mission is to become a cradle for innovative biotechnology companies from around the world. We have developed a scalable business model combing conventional cash-for-service (CFS) CRO work and a unique investment unit with a combination of equity-for-service (EFS) and traditional cash investment. Under the CFS model, Viva provides a one-stop service for novel drug discovery and manufacturing to global pharmaceutical clients. The investment unit is dedicated to investing globally in biotech innovation with novel solutions to unmet medical needs across multiple therapeutic areas. As of December 31, 2020, Viva Biotech has provided drug discovery and production services to 1,252 pharmaceutical clients worldwide, and incubated/invested 67 biotech companies.

Viva Biotech has already completed a substantial acquisition of Langhua Pharmaceutical, a CDMO, and SYNthesis, a chemistry CRO company. We will continue building a one-stop service platform for novel drug discovery and manufacturing and assisting global biotech innovators to pursue the "0" to "1" transformation. For more information, please visit www.vivabiotech.com.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com

For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com